We send the latest information from SMC Laboratories.
Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments that target fibrosis. Fibrosis is involved in many diseases, so even if fibrosis is not your direct target, please read on. Fibrosis can occur in many different organs. It is caused by a disruption in the wound healing…
SMC is proud to announce that J2H biotech (KOR) has published the results of their study using our pre-clinical services with STAM™ model in Cell Death & Disease. Title: Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH (Lee et al., Cell Death Dis . 2022) This…
Today, we give you a brief introduction to our proprietary NASH-HCC model (STAM™ model). The STAM™ model was originally developed as a NASH model, but with a 100% incidence of hepatocellular carcinoma (HCC) as early as 20 weeks of age, it is also an excellent platform for oncology research and therapeutic development. The model…
SMC is proud to announce that GN Corporation Co. Ltd (JPN) has published the results of their study using our STAM™ model in BMJ Open Gastroenterology. In this study, the authors observed how two β-glucans derived from the AFO-202 and N-163 strains of black yeast, Aureobasidium pullulans, affected the gut microbiota and fecal metabolome…
SMC is proud to announce that MRM Health (BEL) has published the results of their study using our STAM™ model in Biomedicines. ■Title A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo (Pinheiro et al., Biomedicines. 2022) The above study tested the therapeutic effects of a…
We are pleased to announce that we have expanded our preclinical model lineup by including the “Imiquimod (IMQ)-induced dermatitis model” for psoriasis. Psoriasis is a refractory skin disease that is caused by both genetic and environmental factors. It causes chronic inflammation characterized by the clinical appearance of erythema and scaling of the skin….
Today, we would like to introduce metabolic dysfunction-associated fatty liver disease (MAFLD), a new concept in the study of fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is defined as the presence of fatty liver disease in the absence of any known causes of steatosis. The number of NAFLD cases are growing worldwide due…
Today, I would like to share with you some wonderful and exciting news! Recently, a client of ours from the National Defense Medical College, Dr. Yasuhiro Takihata, gave a presentation on NASH diagnostics at the 40th Annual Meeting of the Japanese Society of Laser Medicine (JSLSM) and was awarded the Annual Meeting Award for his…
Today, I would like to give you a brief introduction into primary sclerosing cholangitis (PSC), as well as our 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine (DDC) mouse model. PSC is a rare, chronic cholestatic liver disease characterized by biliary inflammation that develops into fibrosis and causes intrahepatic and/or extrahepatic bile duct strictures.These strictures impede bile flow within the ducts…
Today, I would like to introduce the relationship between Nonalcoholic steatohepatitis (NASH) and the gut. Factors contributing to the progression of the NASH include oxidative stress, lipotoxicity, and mitochondrial dysfunction, and recently much attention has been focused on gut-liver axis dysfunction. The gut and the liver are connected by a blood vessel called…